Fulgent Genetics (FLGT) EBT (2015 - 2026)

Fulgent Genetics has disclosed EBT across 12 years of filings, most recently posting -$26.0 million for Q1 2026.

• EBT for Q1 2026 came in at -$26.0 million, down 121.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$22.5 million (up 49.24% YoY), and the FY2025 annual result was -$8.3 million, up 82.34% from the prior year.
• EBT came in at -$26.0 million for Q1 2026 at Fulgent Genetics, down from $32.5 million in the prior quarter.
• In the past five years, EBT ranged from a high of $202.0 million in Q1 2022 to a low of -$33.5 million in Q4 2022.
• The 5-year median for EBT is -$11.2 million (2024), against an average of $4.5 million.
• Across the five-year window, EBT tumbled 370.15% in 2024 and soared 1219.4% in 2025, its largest moves.
• Fulgent Genetics' EBT stood at -$33.5 million in 2022, then soared by 106.78% to $2.3 million in 2023, then slumped by 227.95% to -$2.9 million in 2024, then jumped by 1219.4% to $32.5 million in 2025, then tumbled by 179.97% to -$26.0 million in 2026.
• The last three EBT figures came in at -$26.0 million (Q1 2026), $32.5 million (Q4 2025), and -$7.5 million (Q3 2025), per Business Quant data.